NewLimit
NE
NewLimit develops epigenetic reprogramming therapies designed to reset gene regulation in older cells. The company uses high-throughput experiments and computational methods to identify reprogramming factors and delivery approaches. Its goal is to create medicines that improve tissue function and address age-related conditions.
Founded by Brian Armstrong (Co-Founder & Board Member), Blake Byers (Co-Founder), Jacob Kimmel (Co-Founder & CEO), Gregory Johnson (Co-Founder (Head of Machine Learning))
Blended valuation$3.1B
Valuation history
Weekly blended valuation with priced funding rounds marked on the timeline.
$3.2B
blended valuationfunding round
Oct 20, 2025$1.5BOct 5, 2026
All rounds
5 funding rounds, newest first.
| Round | Announced | Raised | Post-money |
|---|---|---|---|
| Series C | Jun 3, 2026 | $435M | $3.1B |
| Series B | Oct 21, 2025 | $45M | — |
| Series C | Oct 20, 2025 | $45M | $1.6B |
| Series B | May 6, 2025 | $129.8M | $804.7M |
| Series A | Jan 7, 2025 | $72.2M | $180.6M |
Investors
28 investors across all rounds.
- KPKleiner Perkins
- FFFounders Fund
- DCDimension Capital
- ABAbstract
- HCHuman Capital
- NVNFDG Ventures
- VEValor Equity Partners
- DADraper Associates
- EGElad Gil
- ESEric Schmidt
Only Legion members can view the full investor roster. Sign in to Legion
Invest in the private markets on Legion
Registered users see full trading activity, every investor, rankings, and live deals.
Data as of Oct 16, 2026. Valuations are estimates blended from primary and secondary-market signals — not investment advice.